These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30588904)

  • 21. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
    Sellers J; Darby RR; Farooque A; Claassen DO
    Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
    Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
    J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
    Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
    Nasrallah HA; Fedora R; Morton R
    Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
    Fredericks D; Norton JC; Atchison C; Schoenhaus R; Pill MW
    Am J Manag Care; 2017 Apr; 23(5 Suppl):S83-S92. PubMed ID: 28715903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
    Hermanowicz S; Hermanowicz N
    Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
    Yuan M; Sperry L; Malhado-Chang N; Duffy A; Wheelock V; Farias S; O'Connor K; Olichney J; Shahlaie K; Zhang L
    Brain Behav; 2017 Jun; 7(6):e00639. PubMed ID: 28638698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's Disease Psychosis and the Marketing of Pimavanserin.
    Daeschler D; Fugh-Berman A
    Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
    Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
    Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
    Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
    Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ
    Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
    Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
    J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
    [No Abstract]   [Full Text] [Related]  

  • 35. Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval.
    Schubmehl S; Sussman J
    Am J Geriatr Psychiatry; 2018 Oct; 26(10):1007-1011. PubMed ID: 30072306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
    Isaacson SH; Coate B; Norton J; Stankovic S
    J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
    Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
    J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
    Ballard CG; Kreitzman DL; Isaacson S; Liu IY; Norton JC; Demos G; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2020 Aug; 77():100-106. PubMed ID: 32712560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series.
    Rothenberg KG; McRae SG; Dominguez-Colman LM; Shutes-David A; Tsuang DW
    Am J Case Rep; 2023 Sep; 24():e939806. PubMed ID: 37775968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clozapine: Efficacy for Parkinson Disease psychosis in patients refractory to pimavanserin.
    Thames BH; Ondo WG
    Parkinsonism Relat Disord; 2023 Apr; 109():105356. PubMed ID: 36905718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.